Objective: Excess body weight is associated with increased risk of developing hepatocellular cancer (HCC), but its effect on HCC-related mortality remains unclear. We performed a systematic review and meta-analysis to assess the association between premorbid obesity and HCC-related mortality.
H epatocellular carcinoma (HCC) accounts for approximately 600,000 deaths annually, and is the second most common cause of cancer-related mortality in men worldwide. 1, 2 Although the reported HCC incidence and mortality is highest in sub-Saharan Africa and East Asia, an estimated 39,230 new HCC cases and 27,170 deaths are expected from HCC in the United States alone in 2016. It is one of few cancers with rising incidence and mortality in the last decade. Rates of rising mortality mirror incidence indicating the highfatality rate. 2 The epidemiology of HCC varies distinctly with geographic region, with hepatitis B being the leading cause of chronic liver diseases and HCC in South East Asia and subSaharan Africa, and nonalcoholic fatty liver disease (NAFLD) being increasingly recognized as one the leading causes of HCC in the West, besides hepatitis C. 3 Paralleling the rise in HCC incidence is the global epidemic of obesity. Approximately 1.9 billion adults are overweight and 600 million are obese worldwide. Obesity has been identified as an independent risk factor for development of HCC. In a meta-analysis of 21 prospective studies comprising 17,624 cases of primary liver cancer, there was a 39% increased risk of HCC per 5-unit increase in body mass index (BMI) (kg/m 2 ). 4 However, there is limited and conflicting data on the impact of obesity on HCC-related mortality. In a landmark study by Calle et al, 5 the liver cancer-related mortality in obese men (BMI, 30 to 34.9 kg/m 2 ) was 1.9 times the number in men with normal BMI (BMI, 18.5 to 24.9 kg/ m 2 ). A similar observation was reported in another large cohort from the United Kingdom where the liver cancerrelated mortality was almost 4 times in obese individuals (BMIZ30 kg/m 2 ) compared with individuals with normal BMI (BMI, 18.5 to 24.9 kg/m 2 ). 6 Besides type 2 diabetes mellitus (T2DM) and alcohol consumption, higher body weight may be an independent prognostic factors for HCCrelated mortality. 7 In a small cohort of 159 patients, an increase in incidence of recurrent disease (16% vs. 8%, P < 0.05) was reported in overweight and obese patients who underwent orthotropic liver transplantation compared with HCC patients with normal BMI. 8 In another study, the 5-year survival rate in patients who underwent repeat hepatectomy for recurrent HCC was also found to be lower in overweight and obese compared with patients who had normal BMI (51% vs. 92%; P < 0.05). 9 Taken together, these results highlight that obesity could be an independent poor prognostic factor in HCC patients who receive appropriate treatment for the primary disease condition.
To understand this association between premorbid obesity and HCC-related mortality better, we performed a systematic review with meta-analysis of prospective observational studies that investigated the association between premorbid BMI and HCC-related mortality.
MATERIALS AND METHODS
We followed the Meta-analysis of Observational Studies in Epidemiology statement for performing and reporting the present meta-analysis, 10 which was conducted following a priori established protocol.
Study Selection
We included studies that reported statistical measures of association (hazard ratio [HR], incidence rate ratio or relative risk, with 95% confidence intervals [CIs] ) between premorbid (ie, at least 1 y before diagnosis of HCC) categories of BMI and HCC-related mortality. Two types of participant populations were considered: studies performed in patients with established HCC, and those performed in cancer-free individuals at inception and followed for development of HCC-related mortality. The high fatality of HCC can be appreciated from the fact that HCC has an annual incidence of 6.2 cases per 100,000 and annual mortality of 5 cases per 100,000. 11, 12 Inclusion was otherwise not restricted by study size, or publication type. Only human studies in the English language were considered. When there were multiple publications from the same cohort, only data from the most recent comprehensive report were included. We excluded case-control and crosssectional studies, studies reporting data on BMI at or after diagnosis of HCC (confounding by underlying disease and therapy) and studies which did not provide a measure of association (precluded statistical analysis).
Data Sources and Search Strategy
First, we conducted a systematic search of MEDLINE, MEDLINE InProcess, Embase, the Cochrane Database of Systematic Reviews, the Cochrane Database of Reviews of Effect, and the Cochrane Central Register of Controlled Trials through March 2016, using a combination of key words or subject headings for HCC/liver cancer, obesity/BMI, mortality, survival, and prognosis. All identified studies were combined in a single reference manager file (EndNote), duplicates were discarded, and the title and abstracts were reviewed by 2 authors independently (A.G. and A.D.) to exclude studies that did not report the association between obesity and mortality in patients with HCC, on the basis of prespecified inclusion and exclusion criteria. The full text of the remaining articles was examined to determine whether it contained relevant information. Disagreements were harmonized by consensus, in conjunction with the senior investigator (S.S.). Second, the reference lists from included original articles and recent reviews and meta-analyses on obesity and mortality were hand searched to identify additional studies. Third, conference proceedings of major oncology and gastroenterology/hepatology conferences (Digestive Diseases Week, Gastrointestinal Cancers Symposium, annual meetings of the American Society of Clinical Oncology, and the European Society of Medical Oncology) from 2010 to 2015, were reviewed for relevant abstracts. Figure 1 summarizes the study identification and selection process.
Data Abstraction and Quality Assessment
Two reviewers independently abstracted data on the following study-related and patient-related characteristics onto a standardized form: (a) study characteristics-last name of primary author, time period of study/year of publication, country/region of the population studied, and study design (pooled cohort vs. cohort, prospective vs. retrospective); (b) patient characteristics-population-type (all HCC patients, or cancer-free participants at inception), total number and number of patients with HCC, demographic, and clinical and treatment characteristics (age, sex, alcohol use, presence of T2DM, history of cirrhosis, chronic hepatitis B and hepatitis C); (c) exposure status-measure of obesity (BMI), definition and categories of obesity, including reference category for analysis, time period of assessing premorbid obesity in relation to HCC diagnosis, and method of assessment (self-reported vs. measured); (d) outcome assessment-all-cause and/or cancerrelated mortality, attrition rate, information source for exposure ascertainment, and outcome assessment; and (e) statistical analysis-HR or relative risk, along with 95% CI, of association between obesity and outcome (using normal category as reference), with adjusted analysis (including variables adjusted for in individual studies), and duration of follow-up. When there were separate data from 1 study on the basis of sex, we extracted them separately. The risk of bias in these prognostic studies, individual studies was assessed by 2 authors independently using the Quality In Prognosis Studies tool, which evaluates validity and bias in studies of prognostic factors across 6 domains: participation, attrition, prognostic factor measurement, confounding measurement and account, outcome measurement, and analysis and reporting. 13 Any discrepancies were addressed by a joint reevaluation of the original article.
Outcomes Assessed
Our primary outcome focused on assessing HCC-related mortality, comparing the mortality risk of the obese participants (BMI > 30 kg/m 2 ) with the normal participants (BMI, <18 to 25 kg/m 2 ) and summarizing these estimates. Similar comparison between overweight participants (BMI, >25 to 30 kg/m 2 ) and normal BMI participants and pooling data to form summary estimates were undertaken. There were minor differences in reported categories of obesity in individual studies, and hence, for standardized interpretation, we calculated mortality risk in obese (BMIZ30 kg/m 2 ) and overweight participants (BMI, 25.0 to 29.9 kg/m 2 ), compared with normal BMI participants. For this analysis, we pooled effects for all BMI categories of BMIZ30 kg/m 2 into a single summary estimate for obese participants, and likewise pooled effects of all BMI categories for BMI 25.0 to 29.9 kg/m 2 into a single summary estimate for overweight participants. For example, where multiple categories of BMI like 25 to 27.4 and 27.4 to 29.9 kg/m 2 were reported, we combined those categories into an overweight category (BMI, 25 to 29.9 kg/m 2 ) and used them for analyses. 14 
Subgroup and Sensitivity Analyses
A priori hypotheses to assess robustness of the analysis and explain potential heterogeneity in the direction and magnitude of effect included location of study (western vs. AsiaPacific), study design (pooled cohorts vs. individual studies), sex (male vs. female), T2DM (present or absent), and alcohol use (present or absent). We planned sensitivity analyses restricting only to studies reporting the association between obesity and mortality in a cohort of patients with established HCC, and stratified analysis by studies that did and did not adjust for baseline cirrhosis, HCC stage, therapeutic modality, and performance status. For subgroup and sensitivity analysis, we used comparisons between overweight and obese individuals, with normal BMI individuals as reference.
Statistical Analysis
We used the random-effects model described by Der Simonian and Laird 15 to calculate summary HR and 95% CI. Maximally adjusted HR, when reported in studies, was used for analysis to account for confounding variables. To estimate what proportion of total variation across studies was because of heterogeneity rather than chance, inconsistency index (I 2 statistic) was calculated; in this, values of <30%, 30% to 59%, 60% to 75%, and >75% were suggestive of low, moderate, substantial, and considerable heterogeneity, respectively. 16 A subgroup analyses was performed by stratifying original estimates per study characteristics (as described above). In this analysis, a P-value for differences between subgroups of <0.10 was considered statistically significant (ie, a value of P < 0.10 suggested that stratifying on the basis of that study characteristic partly explained the heterogeneity observed in the analysis). We assessed for publication bias quantitatively using the Egger regression test (publication bias considered present if Pr0.10), and qualitatively, by visual inspection of funnel plots of the logarithm of HRs versus their SEs. 17, 18 All P-values were 2 tailed. All calculations and graphs were performed using Comprehensive Meta-Analysis version 2 (Biostat, Englewood, NJ).
RESULTS
A total of 1966 unique studies were identified, of which 9 studies fulfilled our inclusion criteria (8 reporting individual cohorts and 1 study reporting pooled data from multiple cohorts) and were included in our study (Fig. 1 ).
Characteristics and Quality of Included Studies
The 9 studies included 1,599,453 participants at baseline, and reported a total of 5705 HCC deaths during follow-up. The minimum follow-up for a study was 1.9 years. For the purposes of data abstraction, all studies were cohort by design (with subjects being followed over time after exposure [BMI], for development of outcome [mortality], though some studies inherently were reported as case-control studies). Although a single study included a cohort of patients with established HCC, 19 8 studies were large cohorts of cancer-free participants at inception, and followed them for development of HCCrelated mortality. The characteristics of the included studies are shown in Table 1 . None of the included studies reported mortality outcomes after adjusting for history of cirrhosis, history of chronic hepatitis B and hepatitis C infection. No study adjusted for or reported HCC stage at diagnosis, underlying etiology, baseline performance status, or treatment modalities used. Five studies were based in North America or Europe (referred to as western populations), including 2 pooled studies, one of which reported data from 4 cohorts based in Switzerland, and the second study reported data from 3 cohorts based in Scotland, the island of Tiree and their relatives in the mainland. 22, 23 Four studies were conducted in the Asia-Pacific region; 1 was a pooled analysis of 39 cohorts in the AsiaPacific Cohort Studies Collaboration. 22 Study size ranged from 14,758 to 900,053 participants at study inception. Across studies, the number of deaths related to HCC, ranged from 51 to 2171. BMI was assessed as the primary measure of obesity in all studies, with premorbid evaluation performed at least 1 year before HCC diagnosis. Five studies reported data stratified by obese and overweight patients, whereas 4 studies combined obese and overweight patients together. Supplemental Table 1 (Supplemental Digital Content 1, http://links.lww.com/AJCO/ A177) depicts the methodological quality of all studies using the Quality In Prognosis Studies tool. The overall risk of bias was moderate; more studies relied on self-reported BMI (5 studies), rather than measured BMI.
Measures of Adiposity and HCC-related Mortality
Of 9 studies, 5 studies observed higher mortality in participants with higher premorbid BMI, and this was statistically significant across all groups of BMI > 30 kg/m 2 in 4 studies. 5, 6, 20, 21, 23 On meta-analysis, comparing HCC-related mortality in participants in the obese category of BMI with the normal category of BMI, we observed that obese HCC participants had almost 2-fold higher HCC-related mortality than participants with normal BMI (adjusted hazard ratio [aHR], 1.96; 95% CI, 1.46-2.46) with moderate heterogeneity (I 2 = 37%) (Fig. 2) . In contrast, on meta-analysis comparing HCC-related mortality in overweight and normal BMI participants, there was no significant association between being overweight and HCC-related mortality (aHR, 1.08; 95% CI, 0.97-1.21) with minimal heterogeneity (I 2 = 0%) (Fig. 2) . On meta-analysis of 4 studies, which compared the combination of obese and overweight participants with the normal BMI Covariates adjusted for :1-age, 2-sex, 3-smoking, 4-diabetes mellitus/fasting glucose, 5-hypertension/blood pressure/antihypertensive medication, 6-race/ethnicity, 7-alcohol intake, 8-socioeconomic status/housing status/occupation, 9-education, 10-hyperlipidemia/hypercholesterolemia/cholesterol levels, 11-region/Nation, 12-reproductive history, 13-hormone replacement therapy use, 14-time since menopause, 15-fat/vegetable consumption, 16-aspirin use, 17-marital status, 18-physical activity/exercise, 19-comorbidities, 20-particular study (in pooled studies), 21-healthy diet, 22-family history of malignancy, 23-skin fold thickness, 24-study year, 25-pulmonary function tests, 26-MI/angina, 27-bronchitis, 28-height, 29-consumption of coffee/fish, 30-history of liver disease, 31-history of disease of gall bladder, 32-history of transfusion, 33-history of insulin use, 34-history of cirrhosis, 35-history of chronic hepatitis B, 36-history of hepatitis C.
BMI indicates body mass index; CI, confidence interval; HCC, hepatocellular cancer; HR, hazard ratio; NA, not available; NR, not reported.
participants, premorbid BMI was not associated with increased HCC-related mortality. However, it is unclear what proportion of patients in these studies were obese (BMI > 30 kg/m 2 ) versus overweight (BMI, 25.0 to 29.9 kg/m 2 ).
Subgroup Analysis
Because of significant differences in outcomes in obese and overweight individuals, further subgroup analyses were limited to 5 studies, which stratified results by obese and overweight categories. An increased mortality in obese participants was observed in studies conducted both in western region (aHR, 2.10; 95% CI, 1.77-2.48), but not Asia-Pacific region (aHR, 1.10; 95% CI, 0.63-1.92) (P interaction = 0.03). A stronger effect size of obesity on HCC-related mortality was also seen in men (aHR, 2.50; 95% CI, 2.02-3.09) compared with women (aHR, 1.45; 95% CI, 1.08-1.97) (P interaction < 0.01). Results were not different in studies that did and did not adjust for T2DM or alcohol use (Table 2) . We were unable to perform stratified analysis of studies that did and did not adjust for cirrhosis, HCC stage, underlying etiology, treatment modality, or performance status, because no studies reported or adjusted for these factors.
Publication Bias
On the basis of the visual inspection of the funnel plot as well as on quantitative measurement using the Egger regression test, there was no evidence of publication bias (P = 0.90).
DISCUSSION
In this systematic review on the basis of 9 studies in over 1.5 million participants with 5705 HCC-related deaths, we observed that obese, but not overweight, individuals have a 2-fold higher risk of HCC-related mortality compared with individuals with normal BMI. This effect is observed primarily in western populations, where hepatitis C and NAFLD are predominant causes of HCC, but not in Asian populations. In addition, the effect is stronger in men, as compared with women.
There exists a cache of evidence demonstrating the meteoric rise in the incidence of obesity around the globe. 26, 27 There has been a parallel rise in the incidence of NAFLDrelated HCC worldwide. 28, 29 Several pooled studies have observed an increased risk of developing HCC with increasing adiposity, as measured by BMI. 30, 31 Although the exact pathophysiology of the development of NAFLD-related HCC remains unclear, there has been several mechanistic links which points toward the chronic inflammatory response to obesity, hyperglycemia, and insulin resistance, which contribute significantly in the development of HCC. These proinflammatory responses along with decrease in antiinflammatory pathways and decrease in adipokines shifts the internal milieu of hepatocytes in favor of chronic inflammation without adequate repair mechanisms that facilitates tumor growth. 32 Cellular mechanisms involving aberrant proliferation of hepatic progenitor cells and modification of the hedgehog signaling pathways facilitating such uncontrolled proliferation have been implicated in NAFLD-related HCC. 32 The potential reasons for the negative prognostic effect of obesity on HCC-related mortality are likely multifactorial. First, obesity predisposes to metabolic syndrome, and subsequent chronic liver diseases, which increase the risk of HCC and cirrhosis. Unfortunately, none of the studies adjusted for presence or severity of cirrhosis, so it is difficult to tease out the independent effect of obesity on HCC-related mortality. Second, obese patients are significantly more likely to have suboptimal HCC surveillance, because of poor ultrasound quality. Surveillance is recommended in high-risk patients with the intention to identify early lesions (within Milan criteria), which may be amenable to curative resection or liver transplantation. 33 In a cohort study of 941 patients, obese patients had 3-to 8-fold higher risk of having an inadequate surveillance examination, with increasing risk of failure with increasing BMI; over 45% of patients with BMI > 30 kg/m 2 , NAFLD or alcoholic liver disease as underlying etiology and Child B or C cirrhosis had inadequate examinations. 34 Hence, because of delay in detection, obese patients with HCC may be at an advanced stage at diagnosis, resulting in poor prognosis. Included studies did not adjust for underlying stage and treatment for HCC. Third, obese patients are also at higher risk of postsurgical complications, including risk of hepatic decompensation, bile leakage, and wound infections, which can contribute to postoperative mortality. 35 We have previously demonstrated increased mortality in pancreatic cancer patients with elevated premorbid BMI, 36 and a paracrine effect of abdominal adiposity on increased locoregional cancer risk cannot be excluded. However, none of the studies reported the relationship between abdominal obesity (waist hip ratio, or image-estimated visceral adipose tissue) and HCC-related mortality. In contrast to the detrimental effect of excess body weight in HCC and pancreatic cancer, a prior study demonstrated improved outcomes in obese lung cancer patients. 37 It is unclear if this reflects unmeasured confounding, or a true representation of the "obesity paradox," a phenomenon where overweight patients with certain chronic medical conditions have lower mortality than normal weight counterparts. These discrepant findings in site-specific cancer mortality point toward the tremendous heterogeneity in cancer biology and pathophysiology by site, and highlight the need for further study. [38] [39] [40] The strengths of this systematic review include: (a) comprehensive and systematic literature search with welldefined inclusion criteria, carefully excluding redundant studies and studies in which BMI was assessed at the time of or after HCC diagnosis; (b) rigorous evaluation of study quality using a validated tool for prognostic studies; (c) subgroup and sensitivity analyses to evaluate the stability of findings, regardless of presence or absence of heterogeneity; and (d) assessment of a dose-response relationship using obese versus overweight approach, adding biological credibility to findings.
There are several limitations in our study. The metaanalysis included only observational studies, with inherent biases and suboptimal control of confounders. Most studies were large cohort studies, which enrolled cancer-free participants at baseline and followed them for development of several outcomes including HCC-related mortality; these studies did not adjust for competing risk such as presence, etiology and severity of cirrhosis, and HCC stage and treatment. To address this, we performed subgroup analyses on the basis of history of alcohol use and past medical history of T2DM, and observed a stable association. Our subgroup analyses were not driven by a desire to explore sources of heterogeneity, but to verify stability of findings in different conditions. We did not specifically analyze all-cause and cancer-related mortality because of paucity of such data in the included studies. The included studies had inherent limitations-the categories for BMI were not uniformly reported. Exposure assessment in studies was at variable time points, but all consistently before diagnosis of HCC, to minimize confounding by severity. Only one of the studies in this meta-analysis used self-reported BMI; however, the effect of this is likely minimal as self-reported BMI has been shown to be highly correlated with measured BMI. 41 Outcomes assessment was based primarily on record linkage with death certificates for population-based studies; however, these databases have been studied extensively in the past with high validity. Only English language articles were considered. Several studies did not report data on physical activity; studies have shown that fitness more than fatness may correlate with prognosis in cardiovascular disease. 42 We were unable to analyze other measures of adiposity such as waist circumference, visceral versus subcutaneous fat, and percent body fat.
CONCLUSIONS
We observed that premorbid obesity is associated with a 2-fold higher risk of HCC-related mortality, particularly in men, and in western populations. In current treatment schemes, premorbid obesity should be considered as a marker of poor prognosis, and may be used as a stratification variable in interventional studies. In addition, alternative screening modalities may be considered for obese patients to increase diagnostic yield and early detection of HCC.
